Monitoring for Gastroparesis Symptoms While on Ozempic: A Guide for Clinicians

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Literacy to Specific Medication Risks

If you are taking Ozempic and experiencing persistent nausea, bloating, or abdominal pain, these may be signs of gastroparesis. This guide outlines the key symptoms to track and the follow-up evaluations clinicians use to assess delayed gastric emptying. The long-standing tradition of patient education in medicine has always emphasized understanding treatment risks, and this page continues that effort by providing clear, actionable information on monitoring for Ozempic-related gastroparesis.

The Link Between Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its pharmacological action slows gastric emptying, a mechanism that can contribute to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has emerged as a significant concern. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, postprandial fullness, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath testing to confirm delayed emptying. The link between Ozempic and gastroparesis is supported by the drug's known effect on gastric motility and by reported adverse events in clinical trials and post-marketing surveillance. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, which aligns with the mechanistic pathway of delayed gastric emptying.

Mechanism, Warnings, and Legal Considerations in Texas

The mechanistic pathway linking Ozempic to gastroparesis involves the drug's action as a GLP-1 receptor agonist. GLP-1 receptors are expressed in the gastrointestinal tract, and activation slows gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This effect is intended to reduce postprandial glucose excursions but can become pathological in susceptible individuals, leading to symptomatic gastroparesis. The timeline between exposure and documented harm varies; symptoms often emerge during dose escalation, as noted in clinical trials, but may also develop after prolonged use. Post-marketing reports have described cases of gastroparesis requiring medical intervention, including hospitalization. Regarding the adequacy of warnings, the Ozempic prescribing information includes gastrointestinal adverse reactions in the label but does not explicitly list gastroparesis as a warning or precaution. The label mentions hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not specifically address gastroparesis. This omission may be relevant for patients who develop severe or persistent symptoms. The absence of a specific warning could affect legal considerations regarding informed consent and product liability. For affected patients in Texas, the statute of limitations for filing a product liability lawsuit related to Ozempic and gastroparesis is generally two years from the date the injury was discovered or should have been discovered. Texas Civil Practice and Remedies Code Section 16.003 governs personal injury claims. The discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Ozempic caused their gastroparesis. Given the timeline between exposure and harm, patients who experienced symptoms during dose escalation or within months of starting treatment should be aware of this deadline. Settlement-related considerations include the strength of evidence linking Ozempic to gastroparesis, the adequacy of warnings, and the severity of the patient's condition. Settlement amounts may vary based on medical expenses, lost wages, pain and suffering, and punitive damages if gross negligence is shown. In summary, Ozempic use is associated with gastrointestinal adverse reactions, including those consistent with gastroparesis, as evidenced by clinical trial data. The mechanistic link through delayed gastric emptying is plausible. Patients in Texas should be aware of the two-year statute of limitations and seek legal counsel promptly if they believe they have been harmed.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for an Ozempic gastroparesis lawsuit in Texas?

In Texas, the statute of limitations for filing a product liability lawsuit related to Ozempic and gastroparesis is generally two years from the date the injury was discovered or should have been discovered, as governed by Texas Civil Practice and Remedies Code Section 16.003. The discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Ozempic caused their gastroparesis.

Does Ozempic's label include a warning about gastroparesis?

The Ozempic prescribing information includes gastrointestinal adverse reactions in the label but does not explicitly list gastroparesis as a warning or precaution. The label mentions hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not specifically address gastroparesis. This omission may be relevant for legal considerations regarding informed consent and product liability.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.